IOL CHEMICALS & PHARM. 2020-21 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IOL CHEMICALS & PHARM. 2020-21 Annual Report Analysis
Mon, 6 Sep

IOL CHEMICALS & PHARM. has announced its results for the year ended March 2021. Let us have a look at the detailed performance review of the company during FY20-21.

IOL CHEMICALS & PHARM. Income Statement Analysis

  • Operating income during the year rose 3.8% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 3.1% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 30.1% in FY21 as against 30.3% in FY20.
  • Depreciation charges increased by 8.9% and finance costs decreased by 72.1% YoY, respectively.
  • Other income grew by 51.7% YoY.
  • Net profit for the year grew by 23.0% YoY.
  • Net profit margins during the year grew from 18.9% in FY20 to 22.3% in FY21.

IOL CHEMICALS & PHARM. Income Statement 2020-21

No. of Mths Year Ending 12 Mar-20* 12 Mar-21* % Change
Net Sales Rs m 18,945 19,670 3.8%
Other income Rs m 160 243 51.7%
Total Revenues Rs m 19,105 19,913 4.2%
Gross profit Rs m 5,739 5,918 3.1%
Depreciation Rs m 357 389 8.9%
Interest Rs m 209 58 -72.1%
Profit before tax Rs m 5,332 5,714 7.2%
Tax Rs m 1,720 1,268 -26.2%
Profit after tax Rs m 3,613 4,446 23.0%
Gross profit margin % 30.3 30.1
Effective tax rate % 32.2 22.2
Net profit margin % 18.9 22.3
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



EV Stocks: A Hidden Way to Tap into the Massive 15x EV Opportunity

IOL CHEMICALS & PHARM. Balance Sheet Analysis

  • The company's current liabilities during FY21 down at Rs 4 billion as compared to Rs 5 billion in FY20, thereby witnessing an decrease of -4.6%.
  • Current assets rose 37% and stood at Rs 12 billion, while fixed assets rose 18% and stood at Rs 6 billion in FY21.
  • Overall, the total assets and liabilities for FY21 stood at Rs 18 billion as against Rs 13 billion during FY20, thereby witnessing a growth of 30%.

IOL CHEMICALS & PHARM. Balance Sheet as on March 2021

No. of Mths Year Ending 12 Mar-20* 12 Mar-21* % Change
Networth Rs m 8,042 12,604 56.7
 
Current Liabilities Rs m 4,536 4,328 -4.6
Long-term Debt Rs m 0 0 0.0
Total Liabilities Rs m 13,469 17,523 30.1
 
Current assets Rs m 8,479 11,645 37.3
Fixed Assets Rs m 4,990 5,878 17.8
Total Assets Rs m 13,469 17,523 30.1
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



IOL CHEMICALS & PHARM. Cash Flow Statement Analysis

  • IOL CHEMICALS & PHARM.'s cash flow from operating activities (CFO) during FY21 stood at Rs 4 billion on a YoY basis.
  • Cash flow from investing activities (CFI) during FY21 stood at Rs -3 billion, an improvement of 72.2% on a YoY basis.
  • Cash flow from financial activities (CFF) during FY21 stood at Rs -583 million, an improvement of 79% on a YoY basis.
  • Overall, net cash flows for the company during FY21 stood at Rs 43 million from the Rs 147 million net cash flows seen during FY20.

IOL CHEMICALS & PHARM. Cash Flow Statement 2020-21

Particulars No. of months 12 12 % Change
Year Ending Mar-20 Mar-21
Cash Flow from Operating Activities Rs m 4,708 3,798 -19.3%
Cash Flow from Investing Activities Rs m -1,842 -3,173 -
Cash Flow from Financing Activities Rs m -2,719 -583 -
Net Cash Flow Rs m 147 43 -71.0%
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for IOL CHEMICALS & PHARM.

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 75.7, an improvement from the EPS of Rs 63.5 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 559.7, stands at 8.6 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 2.5 times, while the price to sales ratio stands at 1.6 times.
  • The company's price to cash flow (P/CF) ratio stood at 6.8 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-20* 12 Mar-21*
Sales per share (Unadj.) Rs 333.0 335.0
TTM Earnings per share Rs 63.5 75.7
Diluted earnings per share Rs 61.5 75.7
Price to Cash Flow x 8.0 6.8
TTM P/E ratio x 8.3 8.6
Price / Book Value ratio x 1.6 2.5
Market Cap Rs m 31,837 32,855
Dividends per share (Unadj.) Rs 3.0 6.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for IOL CHEMICALS & PHARM.

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 2.7x during FY21, from 1.9x during FY20. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 99.0x during FY21, from 26.5x during FY20. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 35.3% during FY21, from 44.9% during FY21. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 45.8% during FY21, from 68.9% during FY20. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 25.7% during FY21, from 28.4% during FY20. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-20* 12 Mar-21*
Current ratio x 1.9 2.7
Debtors’ Days Days 5 6
Interest coverage x 26.5 99.0
Debt to equity ratio x 0.0 0.0
Return on assets % 28.4 25.7
Return on equity % 44.9 35.3
Return on capital employed % 68.9 45.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how IOL CHEMICALS & PHARM. has performed over the last 5 years, please visit here.

IOL CHEMICALS & PHARM. Share Price Performance

Over the last one year, IOL CHEMICALS & PHARM. share price has moved down from Rs 751.6 to Rs 559.7, registering a loss of Rs 192.0 or around 25.5%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 26,760.0 (up 0.0%). Over the last one year it has moved up from 18,734.2 to 26,760.0, a gain of 8,026 points (up 42.8%).

Overall, the S&P BSE SENSEX is up 49.2% over the year.

(To know more, check out historical annual results for IOL CHEMICALS & PHARM. and quarterly results for IOL CHEMICALS & PHARM.)

Equitymaster requests your view! Post a comment on "IOL CHEMICALS & PHARM. 2020-21 Annual Report Analysis". Click here!

  

Related Views on News

IOL CHEMICALS & PHARM. Announces Quarterly Results (1QFY22); Net Profit Down 47.5% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, IOL CHEMICALS & PHARM. has posted a net profit of Rs 670 m (down 47.5% YoY). Sales on the other hand came in at Rs 5 bn (up 12.7% YoY). Read on for a complete analysis of IOL CHEMICALS & PHARM.'s quarterly results.

More Views on News

Most Popular

Is it Time to Switch from Tata Power to NTPC?(Profit Hunter)

Oct 11, 2021

Given the huge run up in Tata Power, does it make sense to switch to NTPC?

Modi's Big Move Could Boost these 5 Defence Stocks(Views On News)

Oct 11, 2021

To corporatise the defence sector, the Ministry of Defence (MoD) has dissolved the 250-year-old Ordnance Factory Board (OFB).

5 Green Energy Stocks to Watch as India Readies for a Revolution(Views On News)

Oct 13, 2021

The excitement around green energy stocks has opened up a huge contrarian opportunity in the traditional energy space.

Could HDFC Bank be a Big EV Winner? The Answer Will Surprise You...(Profit Hunter)

Oct 13, 2021

Why should investors take it for granted that India's Tesla will be one of the major auto stocks?

Massive Surge in the Shares of Tata Motors Today. Key Factors Favouring the Rally(Views On News)

Oct 13, 2021

Tata Motors zooms 23% after report of TPG investing Rs 75 bn in EV arm.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK IOL CHEMICALS & PHARM.

  • Track your investment in IOL CHEMICALS & PHARM. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON IOL CHEMICALS & PHARM.

IOL CHEMICALS & PHARM. - TEVA PHARMA COMPARISON

COMPARE IOL CHEMICALS & PHARM. WITH

MARKET STATS